Leerink Partnrs Has Bearish Outlook for Repligen Q1 Earnings

Repligen Co. (NASDAQ:RGEN) – Leerink Partnrs decreased their Q1 2025 EPS estimates for Repligen in a report issued on Thursday, February 20th. Leerink Partnrs analyst P. Souda now anticipates that the biotechnology company will post earnings per share of $0.35 for the quarter, down from their prior forecast of $0.39. The consensus estimate for Repligen’s current full-year earnings is $1.72 per share. Leerink Partnrs also issued estimates for Repligen’s Q4 2025 earnings at $0.51 EPS, FY2025 earnings at $1.72 EPS and FY2026 earnings at $2.33 EPS.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share for the quarter, topping analysts’ consensus estimates of $0.41 by $0.03. The company had revenue of $167.55 million for the quarter, compared to the consensus estimate of $167.58 million. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%.

Several other equities research analysts have also issued reports on the stock. Wolfe Research assumed coverage on shares of Repligen in a research report on Thursday, November 14th. They issued a “peer perform” rating for the company. TD Cowen assumed coverage on shares of Repligen in a research report on Monday, February 10th. They issued a “buy” rating and a $200.00 price objective for the company. StockNews.com lowered shares of Repligen from a “hold” rating to a “sell” rating in a research report on Friday. JPMorgan Chase & Co. increased their price objective on shares of Repligen from $190.00 to $200.00 and gave the stock an “overweight” rating in a research report on Friday. Finally, Royal Bank of Canada increased their price objective on shares of Repligen from $203.00 to $205.00 and gave the stock an “outperform” rating in a research report on Friday. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat, Repligen currently has an average rating of “Moderate Buy” and a consensus price target of $181.00.

Repligen Stock Performance

NASDAQ:RGEN opened at $158.99 on Monday. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. The company has a market cap of $8.91 billion, a P/E ratio of -311.75, a P/E/G ratio of 4.54 and a beta of 0.99. Repligen has a fifty-two week low of $113.50 and a fifty-two week high of $203.13. The firm’s 50 day moving average is $155.22 and its two-hundred day moving average is $148.59.

Institutional Investors Weigh In On Repligen

Large investors have recently added to or reduced their stakes in the company. Signaturefd LLC grew its holdings in Repligen by 172.2% during the 4th quarter. Signaturefd LLC now owns 196 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 124 shares in the last quarter. Sava Infond d.o.o. acquired a new position in Repligen during the 4th quarter worth $29,000. Raiffeisen Bank International AG acquired a new position in Repligen during the 4th quarter worth $29,000. Blue Trust Inc. grew its holdings in Repligen by 113.4% during the 3rd quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company’s stock worth $36,000 after acquiring an additional 127 shares in the last quarter. Finally, Resources Management Corp CT ADV acquired a new position in Repligen during the 3rd quarter worth $37,000. 97.64% of the stock is owned by institutional investors and hedge funds.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.